Articles tagged with Heart Failure
A randomized clinical trial of 2,858 patients with new-onset and worsening chronic heart failure shows that torsemide and furosemide have no significant difference in clinical or patient-reported outcomes at 12 months. Torsemide is associated with better outcomes for patients with de novo heart failure.
A three-year intensive treatment strategy to lower systolic blood pressure below 120mmHg significantly reduced cardiovascular events, including heart attack, stroke, and death, compared to standard treatment. The study found that participants in the intensive group experienced fewer major vascular events and deaths over a two-year period.
Patients with heart failure treated with dapagliflozin experienced frequent initial estimated glomerular filtration rate declines, but without increased cardiovascular or kidney event risks. The study suggests that sodium-glucose cotransporter-2 inhibitors can be safely continued in patients experiencing eGFR decline.
A randomized controlled trial suggests that a more liberal approach to red blood cell transfusions for heart attack patients with anemia may benefit outcomes without significant risk. The study found no statistically significant difference between two transfusion strategies, but results suggest a possible benefit of liberal transfusions.
A natural language processing model was validated to identify heart failure hospitalizations in a multicenter clinical trial, demonstrating its potential to improve the efficiency of future trials. The study suggests that natural language processing can be used at scale to identify clinical events, but further research is needed.
A randomized clinical trial found that avoiding aspirin as part of an antithrombotic regimen reduces bleeding events without increasing thromboembolism risk in patients with advanced heart failure treated with left ventricular assist devices. The study suggests that aspirin avoidance may be a viable option for these patients.
A new risk calculator estimates a person's risk for cardiovascular disease (CVD) over the next 30 years by combining measures of cardiovascular, kidney, and metabolic health. The PREVENT risk calculator uniquely quantifies risks for CVD for each biological sex, without including race as a factor.
Researchers at the University of São Paulo have tested a synthetic molecule called AD-9308, which has shown potential in treating heart failure by activating the enzyme aldehyde dehydrogenase 2. The study found that the molecule improved mitochondrial filtration, eliminating cellular pollutants and boosting heart function by up to 40%.
The American Heart Association has selected five finalists in its 6th annual Health Tech Competition to present their innovative technologies. The competition aims to drive technology innovation and transform the landscape of heart and brain health.
A new study by UC San Francisco found that poor sleep is significantly associated with a 15% greater risk of experiencing atrial fibrillation the next day. The researchers suggest strategies like going to bed at a reasonable time, avoiding alcohol and caffeine before bedtime, and exercising regularly to improve general sleep quality.
Dr. Marc A. Pfeffer will receive the 2023 Eugene Braunwald Academic Mentorship Award for his remarkable teaching and mentoring career, which has inspired numerous professionals in cardiovascular medicine. He is credited with directly mentoring 58 individuals throughout their careers.
A new classification system for heart attacks based on heart muscle damage is released, offering a more differentiated definition and improving understanding of acute atherothrombotic MI. This system has the potential to stratify risk more accurately and lay the groundwork for development of injury-stage-specific therapies.
The study analyzed global data from the past three decades, revealing an overall increase in hypertensive heart disease (HHD) prevalence but a decrease in mortality and disability-adjusted life years (DALYs). The burden of HHD is particularly concerning for healthcare systems due to higher prevalence with lower mortality rates.
Researchers investigated the paradoxical prognosis of cardiac sarcoidosis, finding that isolated heart condition patients have poorer outcomes due to history of atrial fibrillation and impaired heart function. Steroid treatment responds equally well in both groups.
Researchers found that Porphyromonas gingivalis inhibits autophagosome-lysosome fusion, worsening cardiac remodeling and causing cardiac rupture after myocardial infarction. The study suggests that treating this oral infection could help prevent fatal heart attacks.
Mutations in the PRDM16 gene alter heart muscle cell metabolism, leading to weakened hearts and increased risk of congenital heart failure in women. Female mice with this genetic defect experience significantly more heart problems than males.
A study by researchers from National Institutes of Health and Glasgow University found that amlodipine does not activate calcium channels, contradicting earlier concerns. The medication remains a recommended first-line treatment for high blood pressure, reducing deaths from hypertension.
Research reveals increased sympathetic nerve activity and reduced exercise capacity in patients with heart failure resulting from anthracycline chemotherapy. Sympathetic neural overdrive is associated with skeletal myopathy and decreased cardiac function.
Leading professional organizations announce first-time multidisciplinary consensus guidelines for essential and comprehensive care centers in the US. The guidelines aim to address known variation in outcomes at different centers, providing structure, process, and outcome components necessary for quality care.
A study showed that yoga therapy can improve heart failure patients' endurance, strength, balance, symptom stability, and overall quality of life. Additionally, echocardiographic parameters revealed improved left ventricular systolic function in the yoga group compared to the non-interventional group.
Researchers at the University of Alabama at Birmingham found that BNP levels are high in end-stage heart failure patients with cardiogenic shock, but no longer a reliable predictor of clinical outcomes after ventricular assist device (VAD) implantation. This study suggests reevaluating routine use of BNP testing for these patients.
Researchers at the University of Alabama at Birmingham have developed a modified messenger RNA that can temporarily induce cardiomyocyte cell division, leading to reduced infarct size and improved heart function. The treatment has shown promise in mouse and pig models without increasing the risk of deadly arrhythmias.
Research reveals that heart transplant recipients from economically disadvantaged areas are at a greater risk of graft failure and mortality, with a 10% increased relative risk compared to those from non-distressed communities. The disparity in outcomes has widened since the implementation of the 2018 UNOS Heart Allocation policy.
A new study published in the Journal of the American Heart Association found that stressful life events and poor sleep are major contributing factors to irregular heart rhythms after menopause. The study analyzed data from over 83,000 women aged 50-79 and found a significant association between stress, insomnia, and atrial fibrillation.
A recent clinical trial led by Professor Holger Thiele found that ECLS does not reduce 30-day mortality after cardiogenic shock, but is associated with more complications. The study involved 420 patients and compared ECLS therapy with standard intensive care unit treatment.
The HEART-FID trial found that ferric carboxymaltose did not improve a composite outcome of death, heart failure hospitalizations, and exercise function in patients with heart failure with reduced ejection fraction and iron deficiency. The study met its primary endpoint for safety but fell short of demonstrating efficacy.
A focused update of the European Society of Cardiology (ESC) Heart Failure Guidelines incorporates latest evidence-based treatments for improved patient outcomes. New recommendations include SGLT2 inhibitors and intensive treatment strategies to reduce hospitalization and mortality.
The Texas Heart Institute has received a five-year, $2 million grant from the National Institutes of Health to advance organ bioengineering. The project aims to develop transplantable bioartificial hearts to combat end-stage heart failure.
A new study found that catheter ablation significantly lowers the incidence of cardiovascular events and death in very old patients with nonvalvular atrial fibrillation. The researchers compared 208 patients who underwent AF ablation with those who received medical therapy only, finding a lower risk of both cardiovascular events and de...
A new study found that a simple blood test can predict the risk of progressive heart and kidney disease in people with Type 2 diabetes. The test measures levels of four biomarkers, which fell after treatment with canagliflozin, a type 2 diabetes medicine.
Researchers at Brigham and Women's Hospital have developed an AI model that screens electrocardiograms (ECG) for signs of atrial septal defects (ASD), a common adult congenital heart disease. The model correctly detected ASD in 93.7% of cases, outperforming traditional methods.
A new kidney function equation has been shown to be more accurate than the old equation in estimating kidney function, particularly for Black individuals. This new equation may reduce racial disparities in cardiovascular disease by making previously ineligible patients eligible for heart failure therapies.
A French study found that recreational drug use was associated with a nearly 9-fold higher rate of death or need for emergency intervention in cardiac intensive care patients. The study detected various substances in 1 in 10 patients, with cannabis being the most frequently detected substance.
A new diagnostic method assesses electrical and mechanical activity in the heart during atrial fibrillation, providing personalized assessment of atrial remodeling. This can help predict disease progression and guide treatment.
Researchers found that African ancestry patients with dilated cardiomyopathy have fewer clinically actionable variants in DCM genes compared to European ancestry patients. The study enrolled 1,198 patients with dilated cardiomyopathy, revealing a racial imbalance in genetic trials for heart failure.
Researchers found that stable, long-term elevation in urinary albumin excretion is associated with a high risk of new-onset heart failure and mortality. Persistently high levels were linked to older patients and those with conditions like diabetes and previous heart attacks.
A new multi-center study found that having a genetic variant in the prealbumin gene alone is not sufficient for diagnosing transthyretin amyloid cardiomyopathy in older Black patients. Researchers suggest that a blood test measuring prealbumin levels may be useful in identifying patients at risk of developing cardiac amyloidosis.
A study published in JACC: Heart Failure found that people with heart failure who increase their daily step count experience improvements in health status over a 12-week period. The study suggests that wearable device data, such as step counts, can be clinically significant and inform future clinical trials and care.
A study found that taking more daily steps improves symptoms and physical limitations for people with heart failure, with little association seen beyond 5,000 steps. Participants who increased their step counts experienced improved symptom control and physical function.
Octapharma's Balfaxar, a prothrombin complex concentrate, has received FDA approval for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy. The product demonstrated effective hemostasis in 94.6% of patients and was non-inferior to comparator Kcentra.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
Researchers developed a new method to detect hypertrophic cardiomyopathy (HCM) using combined cardiac diffusion tensor imaging and cardiac MRI perfusion scans. The study identified abnormal microstructure and microvascular disease in people with genetic mutations but no symptoms, allowing for early detection of the condition.
A study analyzing 89,000 individuals found that engaging in intense physical activity over a short period (weekend warrior pattern) lowers the risk of atrial fibrillation, heart attack, heart failure, and stroke. This type of activity was associated with similar lower risks compared to evenly distributed physical activity.
A new study published in Circulation journal found that Black adults living in areas historically affected by discriminatory housing practices had a higher heart failure risk. The analysis included over 2.3 million adults from 2014-2019 and mapped historical redlining maps onto modern day maps of US zip codes.
In a groundbreaking procedure, Adriana Rodriguez received a dual-organ transplant, with her healthy liver transplanted into another patient to mitigate rejection risk. This innovative approach, known as HALT-D, demonstrates the potential for immunoprotection and has implications for highly sensitized patients requiring multiple organs.
Researchers analyzed data from the first genetically-modified pig heart transplant into a human patient and found that several overlapping factors contributed to heart failure, including poor pre-transplant health, immunocompromised state, and use of intravenous immunoglobulin. The study provides crucial insight into how these factors ...
Researchers found that when a patient's congestive heart failure is mentioned during the initial check-in process, emergency room physicians are less likely to test for pulmonary embolism, potentially leading to delays in diagnosis. This anchoring bias can delay crucial testing and diagnosis of deadly medical conditions.
Researchers developed a more accurate model of human cardiac fibrotic tissue, which could enable quicker drug testing and potentially lead to new therapies for heart failure. The model, built using an electrospinning technique, recreates the unique aspects of scarred cardiac tissue.
The new scientific statement highlights the importance of identifying the root cause of pediatric cardiomyopathy to develop effective treatment strategies. Genetic testing is recommended for all children with cardiomyopathy, which may lead to financial and emotional cost savings.
A large-scale registry study found that older autistic adults have a significantly higher risk of injury, especially self-inflicted, and physical conditions such as type 2 diabetes and anaemia. Autistic individuals had a seven-fold risk of self-harm compared to non-autistic people.
A new study found that most adults with Type 2 diabetes in Alabama Medicaid did not receive follow-up healthcare within the recommended two-week period after a heart failure hospitalization. African American and Hispanic adults were particularly affected, with worse follow-up care compared to white adults.
A groundbreaking study has shown that a devastating heart condition can spontaneously reverse in three men, who are now free of symptoms. The condition, transthyretin cardiac amyloidosis, is progressive and previously considered irreversible.
A new study published in Hypertension found that oral estrogen hormone therapy may increase the risk of high blood pressure in women, while transdermal and vaginal formulations appeared to have a lower impact. The research involved over 112,000 women aged 45 years and older who took estrogen-only hormone therapy.
Researchers have developed a test to detect 'zombie' cells in donor blood, which may help increase the number of suitable hearts available for transplant. The test targets proteins associated with senescent cells, which can impact heart health.
Researchers identified five subtypes of heart failure using machine learning, including early onset and atrial fibrillation related. These subtypes have different mortality risks, with some patients at higher risk of dying within a year after diagnosis.
Women with short or long menstrual cycles are at increased risk of cardiovascular disease events such as heart attack or AFib. The study analyzed data from over 58,000 women and found that irregular menstrual cycle length was associated with higher risks of CVD, independent of other factors.
The PARAGLIDE-HF trial found that sacubitril/valsartan significantly reduces plasma NT-proBNP levels compared to valsartan alone in patients with an ejection fraction above 40%. The study also showed a larger treatment effect in those with EF ≤60%, suggesting potential benefits for this population.
The MONITOR-HF trial found that remote pulmonary artery pressure monitoring significantly improved quality of life by 7.1 points at 12 months, with a 44% reduction in heart failure hospitalizations or urgent visits during follow-up. The procedure was safe and reliable, with a high level of adherence to guideline-directed medical therapy.
The new guideline provides guidance on the use of cardiac resynchronization therapy and conduction system pacing in patients with indications for pacemakers or heart failure. The authors emphasize the importance of shared decision-making between providers and patients, and highlight areas for future research.
A study funded by the National Institutes of Health found that vigorous exercise is safe for people with hypertrophic cardiomyopathy, a rare inherited disorder affecting the heart muscle. The research, published in JAMA Cardiology, suggests that restrictions on exercise may be unnecessary for individuals with HCM.